Anthroposophic Pharmacy

Last update: 28.08.2020

Anthroposophic medicinal products are made from raw materials of natural origin, i.e., they are primarily taken from nature. The raw materials include minerals, metals, plants and partial plants, eusocial insects, animal organs and organ derivatives.

Today the pharmaceutical processes of Anthroposophic Pharmacy are well described in the European Pharmacopoeia (Pharmacopoea Europaea), the German Homoeopathic Pharmacopoeia (HAB), the Swiss Pharmacopoeia (Pharmacopoea Helvetica) and the Anthroposophic Pharmaceutical Codex (APC). The APC presents all relevant processes of Anthroposophic Pharmacy in one work.

Many anthroposophic medications are on the market based on specific national legislation. In the European Union, anthroposophic medications are generally regulated according to Directive 2001/83/EC. The Directive mentions anthroposophic medicinal products only in its introductory paragraphs (paragraph 22) and defines that, provided the products are prepared according to the homeopathic method, they should be regulated as homeopathic medicinal products.

The origin, production and application of anthroposophic medicinal products go back to Rudolf Steiner (1861–1925), who founded Anthroposophic Medicine at the beginning of the 20th century together with the physician Ita Wegman (1876–1943). At that time Rudolf Steiner developed principles for the choice of raw materials and the various manufacturing processes that are still valid today. Another pioneer of Anthroposophic Pharmacy was Rudolf Hauschka (1891–1969).

Research news

Phase IV trial: Kalium phosphoricum comp. versus placebo in irritability and nervousness 
In a new clinical study, Kalium phosphoricum comp. (KPC) versus placebo was tested in 77 patients per group. In a post-hoc analysis of intra-individual differences after 6 weeks treatment, a significant advantage of KPC vs. placebo was shown for characteristic symptoms of nervous exhaustion and nervousness (p = 0.020, p = 0.045 respectively). In both groups six adverse events (AE) were assessed as causally related to treatment (severity mild or moderate). No AE resulted in discontinuation in treatment. KPC could therefore be a beneficial treatment option for symptomatic relief of neurasthenia. The study has been published open access in Current Medical Research and Opinion
https://doi.org/10.1080/03007995.2023.2291169.


Further information on Anthroposophic Medicine